If you believe artificial intelligence will take up a growing share of energy, Vistra might just be the stock for you.
WILMINGTON, DE — Incyte (Nasdaq: INCY) announced that the U.S. Food and Drug Administration has approved Opzelura (ruxolitinib) cream 1.5% for children as young as two with mild to moderate ...
OppFi’s reliance on a bank‑partnership model exposes it to ongoing “true‑lender” litigation and potential rate‑cap ...
Morgan Stanley raised the firm’s price target on Vistra (VST) to $223 from $207 and keeps an Overweight rating on the shares. The firm is updating ...
The ones we own, Vistra, VST, NRG, these companies are generating 9 and 11% operating cash flows. They’re 70 and 30 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback